Table 2.
Univariate and multivariate analyses of stromal TILs for DFS in SYSUCC and TCGA cohort.
| Variable | SYSUCC cohort (N = 184) |
TCGA cohort (N = 117) |
||||||
|---|---|---|---|---|---|---|---|---|
| Univariate model |
Multivariate model1 |
Univariate model |
Multivariate model2 |
|||||
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Continuous variable | ||||||||
| TILs density (N/mm2) | 0.99 (0.99–1.00) | 0.014 | 0.99 (0.99–1.00) | 0.003 | 0.99 (0.99–1.00) | 0.013 | 0.99 (0.99–1.00) | 0.019 |
| mTILs-1 (%) | 0.96 (0.95–0.98) | <0.001 | 0.96 (0.94–0.98) | <0.001 | 0.97 (0.94–1.00) | 0.028 | 0.97 (0.93–1.00) | 0.067 |
| mTILs-2 (%) | 0.96 (0.94–0.98) | 0.003 | 0.95 (0.93–0.98) | 0.001 | 0.98 (0.96–1.00) | 0.097 | – | – |
| mTILs-3 (%) | 0.96 (0.94–0.98) | <0.001 | 0.95 (0.92–0.98) | <0.001 | 0.99 (0.96–1.01) | 0.230 | – | – |
| aTILs (%) | 0.97 (0.95–0.99) | 0.009 | 0.97 (0.94–0.99) | 0.016 | 0.96 (0.93–0.99) | 0.005 | 0.96 (0.93–0.99) | 0.007 |
| Dichotomous variable | ||||||||
| mTILs-1 (high vs. low) | 0.23 (0.12–0.42) | <0.001 | 0.19 (0.09–0.42) | <0.001 | 0.24 (0.09–0.64) | 0.005 | 0.28 (0.10–0.79) | 0.016 |
| mTILs-2 (high vs. low) | 0.26 (0.14–0.47) | <0.001 | 0.28 (0.14–0.55) | <0.001 | 0.40 (0.15–1.07) | 0.068 | – | – |
| mTILs-3 (high vs. low) | 0.34 (0.18–0.62) | <0.001 | 0.24 (0.11–0.53) | <0.001 | 0.51 (0.19–1.39) | 0.189 | – | – |
| mTILs-con (high vs. low) | 0.24 (0.13–0.44) | <0.001 | 0.23 (0.11–0.47) | <0.001 | 0.30 (0.10–0.87) | 0.027 | 0.32 (0.11–0.91) | 0.032 |
| aTILs (high vs. low) | 0.34 (0.18–0.63) | 0.001 | 0.33 (0.16–0.68) | 0.003 | 0.24 (0.11–0.54) | 0.001 | 0.20 (0.08–0.50) | 0.001 |
TILs, tumor infiltrating lymphocytes; DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; mTILs, manual quantified stromal TILs score;.
aTILs, automated quantified stromal TILs score; mTILs-con, a consensus group generated from individual dichotomized mTILs grouped by three pathologists based on majority voting rule. P-value was calculated using likelihood ratio test. The cut-off values used were 15%, 9%, 10% and 14.1% for mTILs-1, mTILs-2, mTILs-3 and aTILs in SYSUCC cohort and 15%, 20%, 20% and 12.3% for mTILs-1, mTILs-2, mTILs-3 and aTILs in TCGA cohort.
Other variables included in the multivariate analysis were age, histological grade, tumor size, LNM(Y/N), TNM stage, chemotherapy(Y/N) and radiotherapy(Y/N).
Other variables included in the multivariate analysis were age, histological grade, tumor size, LNM(Y/N) and TNM stage.